Ken Griffin Genmab A/S Call Options Transaction History

Citadel Advisors LLC

  • $550 Billion
  • Q2 2025

Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$17.98 - $23.09 $537,602 - $690,391
-29,900 Reduced 62.03%
18,300 $378,000
Q1 2025

May 15, 2025
BUY
$18.69 - $24.14 $607,425 - $784,550
32,500 Added 207.01%
48,200 $943,000
Q4 2024

Feb 14, 2025
BUY
$20.02 - $24.15 $110,110 - $132,825
5,500 Added 53.92%
15,700 $327,000
Q3 2024

Nov 14, 2024
BUY
$23.84 - $28.48 $81,056 - $96,832
3,400 Added 50.0%
10,200 $248,000
Q2 2024

Aug 14, 2024
SELL
$25.13 - $30.27 $165,858 - $199,782
-6,600 Reduced 49.25%
6,800 $170,000
Q1 2024

May 15, 2024
BUY
$26.43 - $32.77 $44,931 - $55,709
1,700 Added 14.53%
13,400 $400,000
Q4 2023

Feb 14, 2024
BUY
$27.94 - $35.44 $30,734 - $38,984
1,100 Added 10.38%
11,700 $372,000
Q3 2023

Nov 14, 2023
BUY
$35.27 - $42.24 $211,620 - $253,440
6,000 Added 130.43%
10,600 $373,000
Q2 2023

Aug 14, 2023
SELL
$37.4 - $42.94 $1.11 Million - $1.28 Million
-29,700 Reduced 86.59%
4,600 $174,000
Q1 2023

May 15, 2023
BUY
$34.88 - $43.22 $1.09 Million - $1.35 Million
31,300 Added 1043.33%
34,300 $1.3 Million
Q4 2022

Feb 14, 2023
SELL
$33.8 - $47.06 $5.75 Million - $8 Million
-170,100 Reduced 98.27%
3,000 $127,000
Q3 2022

Nov 14, 2022
BUY
$31.52 - $373.61 $2.89 Million - $34.2 Million
91,600 Added 112.39%
173,100 $5.56 Million

Others Institutions Holding GMAB

# of Institutions
241
Shares Held
65.2M
Call Options Held
32.5K
Put Options Held
55K
View Full List

About GENMAB A/S

GMAB Quotes by TradingView
  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.4B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email